Fig. 2

Antibody-targeted MASP-2 inhibition significantly reduces neurological deficits and infarct volumes following tMCAO. 10 mg/Kg of the anti-MASP-2 and its respective isotype control (IC) antibody were administered as single doses on 7 and 3.5 days before and 60 min after tMCAO induction (n = 9) (a). Neurological deficits (b) and infarct volumes (c) were assessed 48 h post-tMCAO. Representative images from cresyl violet staining are also shown for each of the experimental groups. Serum was collected 48 h post-tMCAO from MASP-2-antibody or IC pre-treated animals and complement functional activity tested in a lectin pathway-specific ELISA (d) (IC, n = 8; anti-MASP-2 antibody, n = 7). Data are presented as scatter-dot plots with means (bars). *P < 0.05; **P < 0.01, unpaired t test